Navigation Links
Four Independent Research Groups Present Data Generated by Pressure Cycling Technology (PCT) at the ASMS Conference on Mass Spectrometry and Allied Topics in Denver, CO

SOUTH EASTON, Mass., June 9 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) ("PBI") today announced that scientists from Pacific Northwest National Laboratories (PNNL), the Harvard School of Public Health (HSPH), the Commonwealth of Virginia (CoVA) Laboratory, and the Food and Drug Administration (FDA) presented data generated through the use the Company's patented pressure cycling technology (PCT) at last week's (June 1-5) American Society for Mass Spectrometry's 56th Annual Conference in Denver, Colorado. These included three poster presentations and an oral presentation relating to research on biodefense and on improving the preparation of samples for studies of proteins.

According to Dr. Daniel Lopez Ferrer and his colleagues at PNNL, one of the most time-consuming steps in studying proteins is the long incubation period (6-12 hours) required to break (digest) proteins down into their building blocks (peptides), often done with the enzyme trypsin. In their poster presentation, the authors discussed the effect of high pressure (up to 35,000 psi) -- with pressure cycling technology (PCT) and with an on-line high pressure system -- on the tryptic digestion of proteins. They reported that complete digestion of proteins could be achieved in just 60 seconds. The researchers further reported that high pressure digestion "resulted in a noticeable improvement in the number of (peptide) identifications." They concluded that an on-line high pressure system "looked promising for ultra- high throughput applications, i.e., proteomics on the fly."

A major bottleneck in studying obesity and obesity-related diseases (such as diabetes, heart disease, neurological disorders, and some cancers) is the difficulty in extracting proteins from lipid-rich adipose (fat) tissue. Dr. Alexander Ivanov and his colleagues at the HSPH presented updated information on the use of PCT and PCT-dependent reagents (ProteoSolve-LRS Kit) for the efficient recovery of proteins from lipid-rich samples. Dr. Ivanov and his colleagues found that the combination of PCT and ProteoSolve-LRS resulted in a much faster, less expensive, and higher quality extraction process, as compared to current methods.

Similar to the trypsin digestion study carried out by scientists at PNNL, researchers at the CoVA Laboratory also used PCT to "dramatically reduce" the time required for trypsin digestion of proteins and to "simplify the procedure to a few steps." Dr. Shane Wyatt and Dr. Tim Croley concluded that "complete digestion was achieved in less time" with the PCT method than with traditional methods. The authors further concluded that their results pointed to the "applicability of this technique to the rapid analysis of biological agents where identification is paramount."

Dr. John Callahan of the FDA made an oral presentation to an audience of approximately 500 attendees of the Mass Spectrometry in Biodefense session. Dr. Callahan discussed the need for more precise laboratory tools to help differentiate bacteria at the serovar, strain, and substrain levels. In their research study, Dr. Callahan and his colleagues used PCT to extract proteins from E. coli and Salmonella enteri prior to protein profiling. Dr. Callahan reported that further analysis of protein profiles can be used "to identify biomarkers" and to "identify changes induced in bacteria by external conditions." According to Dr. Callahan, this methodology "appears to differentiate different strains of E. coli 0157:H7 isolated from food-borne outbreaks."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and higher) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of enzymes, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include the reported effectiveness of PCT in identifying peptides; the speed and simplicity of sample preparation using PCT compared with current sample preparation methods for trypsin digestion of proteins; the importance of ProteoSolve-LRS and PCT in the reported identification of new proteins; the speed, cost, and quality advantages of ProteoSolve-LRS and PCT over other methods for extracting proteins from lipid-rich adipose (fat) tissue; the use of PCT to extract proteins from E. coli and Salmonella enteri; and the adoption of PCT over other sample preparation methods. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: unforeseen technological difficulties that the Company may encounter in the development of the PCT technology and the PCT Sample Preparation System; the possibility that due to the nature of the research being performed, other laboratories and scientists may not find the use of PCT and ProteoSolve-LRS to be as advantageous as reported by Dr. Lopez Ferrer, Dr. Ivanov, Dr. Wyatt, Dr. Croley, Dr. Callahan, and by their colleagues; due to scientific and medical challenges, the possibility that the data generated and conclusions reached by Dr. Lopez Ferrer, Dr. Ivanov, Dr. Wyatt, Dr. Croley, Dr. Callahan, and by their colleagues, or that may be generated by other researchers in the future, may not be beneficial in the development of new tools for protein extraction and analysis, for the study of obesity and obesity-related diseases, or other procedures and diseases; that due to competitive products, services, and technological advances, PCT may not be the preferred method of sample preparation by other scientists and laboratories; and the other risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website

Investor Contacts:

Richard T. Schumacher, President & CEO

Edward H. Myles, Senior Vice President of Finance & CFO

Pressure BioSciences, Inc.

(508) 230-1828 (T)

SOURCE Pressure BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. InterCure and Mashco Announce Launch into Independent Pharmacies in the United Kingdom
5. Mindray Announces Appointment of Dr. Jixun Lin as Independent Director
6. Roche to Nominate Independent Directors for Election at Ventanas 2008 Annual Stockholders Meeting
7. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R)
8. Kiwa Fertilizers Pass Independent Tests
9. Amarin Appoints Dr. William Mason as Lead Independent Director
10. China Pharma Appoints Three Independent Non-Executive Directors
11. China Technology Appoints Deloitte Touche Tohmatsu CPA as Independent Auditor
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells Group announced the opening of a ... of Arica and Iquique in northern Chile. The facilities are part of GSCG’s expansion efforts ... protocols and techniques in stem cell medicine to patients from around the world. , The ...
(Date:11/30/2015)... , Nov. 30, 2015 Harvard ... ), a biotechnology company developing bioengineered organ implants ... written notification from The NASDAQ Stock Market that ... price requirements. The letter noted that as a ... common stock having exceeded $1.00 per share for ...
(Date:11/30/2015)... , Nov. 30, 2015 Human Longevity, Inc. ... company has acquired Cypher Genomics, Inc., a leading genome ... genomic interpretation software solutions. The San Diego ... HLI including Cypher CEO and Co-founder, Ashley Van Zeeland ... Pediatric Business.  Financial details of the deal were not ...
(Date:11/30/2015)... Germany , November 30, 2015 ... Vienna, Austria to be held December 1-4, 2015. ... in Vienna, Austria to be held ... subsidiary of Vycor Medical, Inc. ("Vycor") (OTCQB: VYCO), announced that ... Suite at the 3rd European Congress of NeuroRehabilitation (ECNR) ...
Breaking Biology Technology:
(Date:11/16/2015)... JOSE, Calif. , Nov 16, 2015 /PRNewswire/ ... developer of human interface solutions, today announced expansion ... Synaptics TouchView ™ touch controller and display ... architectural revolution of smartphones. These new TDDI products ... include TD4100 (HD resolution), TD4302 (WQHD resolution), and ...
(Date:11/10/2015)...  In this report, the biomarkers market ... type, application, disease indication, and geography. The ... consumables, services, software. The type segments included ... biomarkers, and validation biomarkers. The applications segments ... drug discovery and development, personalized medicine, disease ...
(Date:11/2/2015)... 2, 2015  SRI International has been awarded a ... development services to the National Cancer Institute (NCI) PREVENT ... scientific expertise, modern testing and support facilities, and analytical ... and toxicology studies to evaluate potential cancer prevention drugs. ... PREVENT Cancer Drug Development Program is an NCI-supported pipeline ...
Breaking Biology News(10 mins):